Key result
Deprescribing in dialysis aims to reduce pill burden and may mitigate adverse events associated with polypharmacy, including falls, hospitalizations, and mortality risk.
Deprescribing in dialysis patients may reduce pill burden and mitigate adverse events associated with polypharmacy.
“Less is more”, a quote attributed to Ludwig Mies van der Rohe, is now finding increased relevance across several fields, including medicine. Deprescribing is an exemplar of this proverb and describes the process of deliberately withdrawing medications, with the aim of reducing pill burden and improving health and quality of life.1 Deprescribing may mitigate multiple adverse events associated with polypharmacy including falls, cognitive disturbances, hospitalizations and mortality risk.2
No takes yet. Share an insight, caveat, or question.
Vijayan et al. (2024) conducted an editorial in Dialysis. Deprescribing was evaluated. Deprescribing in dialysis aims to reduce pill burden and may mitigate adverse events associated with polypharmacy, including falls, hospitalizations, and mortality risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: